When the parents of a toddler born profoundly deaf learned their child carried mutations in both copies of the OTOF gene, a cochlear implant had been the only path to hearing. That changed on April 23, 2026, when the U.S. Food and Drug Administration approved Otarmeni (lunsotogene parvec-cwha), a one-time treatment developed by Regeneron Pharmaceuticals that delivers a functional copy of the OTOF gene directly into the inner ear. It is the first gene therapy the FDA has approved for any form of inherited hearing loss. Researchers in China, notably a Fudan University and Harvard collaboration, had previously reported positive results from their own OTOF gene therapy trials, but Otarmeni is the first to receive formal FDA clearance.
“This is a moment many families have been waiting for,” Regeneron’s head of genetic medicine said in the company’s public announcement, describing calls from parents who had enrolled children in the trial and witnessed them respond to sound for the first time. Physicians involved in the CHORD study have publicly noted that some treated children began reacting to conversational-level speech within weeks of the procedure, an outcome that, for families who had been told hearing aids would never work for their child, felt transformative.
The approval covers children and adults with severe-to-profound sensorineural hearing loss caused by mutations in both copies of the OTOF gene, a condition that disrupts production of otoferlin, a protein essential for transmitting sound signals from the inner ear’s hair cells to the auditory nerve. Mutations in OTOF account for an estimated 1 to 8 percent of congenital sensorineural hearing loss cases, a small but significant share of the roughly 26,000 babies born with hearing loss in the United States each year. Until now, cochlear implants were the only option for restoring any degree of hearing in these patients.
How the therapy works
Otarmeni is not a pill or a standard injection. It is delivered through intracochlear infusion, a surgical procedure that places the gene therapy directly into the fluid-filled cochlea of the inner ear. The treatment uses a dual-vector adeno-associated virus (AAV) system engineered with a hair-cell-specific promoter to produce functional otoferlin protein where it is needed most.
Preclinical research published in a peer-reviewed study and available through PubMed Central showed that this approach restored auditory brainstem responses in mice lacking functional otoferlin, with hearing recovery that proved durable over the study’s observation period. Those animal results provided the scientific foundation for moving into human trials.
Because the procedure requires precise surgical delivery, it can only be performed at medical centers with otologic surgical expertise and the infrastructure to support genetic testing, preoperative imaging, and long-term audiologic follow-up. Patients must have preserved outer hair cell function and cannot have a cochlear implant in the ear being treated.
What the clinical trial showed
The FDA based its decision on results from the CHORD trial (NCT05788536), a study that enrolled children and infants ages roughly 1 to 17 with confirmed biallelic OTOF mutations. The safety population included 24 patients. According to the ClinicalTrials.gov registry, some participants received unilateral dosing (one ear) while others received bilateral dosing (both ears), reflecting protocol amendments that expanded the study over time. Reported outcomes centered on measurable improvements in auditory thresholds and speech perception, which the agency judged reasonably likely to predict meaningful gains in real-world communication and language development.
The approval came through the FDA’s accelerated approval pathway, a mechanism reserved for therapies that address serious conditions and demonstrate a meaningful advantage over existing treatments based on early evidence. Regeneron filed its Biologics License Application on December 23, 2025, and the review was expedited under the Commissioner’s National Priority Voucher pilot program. Under this pilot, the FDA can grant a transferable voucher to the sponsor of an approved high-impact therapy; that voucher can then be used, or sold to another company, to obtain priority review for a future, unrelated application, creating a financial incentive for developing treatments for conditions that might otherwise lack commercial appeal.
Accelerated approval carries obligations. Regeneron must complete confirmatory trials to verify that the hearing improvements seen in the CHORD study translate into lasting clinical benefit. The FDA’s product page for Otarmeni outlines additional postmarketing requirements, including long-term follow-up of treated patients and continued monitoring for immune and inflammatory reactions within the cochlea.
Open questions about durability, cost, and access
The 24-patient trial, while groundbreaking, leaves significant questions unanswered. Chief among them is durability. Whether the restored hearing persists for years or decades matters enormously for pediatric patients who may receive the therapy in infancy. A treatment that provides only a few years of benefit would raise very different clinical and ethical considerations than one that sustains hearing into adulthood. At this stage, clinicians are relying on limited follow-up windows and extrapolation from animal models rather than definitive multi-year human data.
Pricing has not been disclosed. For context, Luxturna, an AAV-based gene therapy for inherited retinal blindness approved in 2017, carries a list price of roughly $850,000 for both eyes. Zolgensma, a gene therapy for spinal muscular atrophy, costs approximately $2.1 million per treatment. Otarmeni’s price has not been confirmed by Regeneron or any payer, but the precedent set by comparable gene therapies suggests it will be substantial. Insurance coverage decisions, hospital readiness, and the geographic availability of qualified surgical centers will all determine how quickly eligible families can actually access the treatment.
The small trial size also means rare adverse effects could surface only after broader use. No post-market safety reports specific to Otarmeni have appeared in federal adverse event databases, which is expected given the recent approval date. Delayed inflammatory responses, unexpected impacts on vestibular function, or other complications may only become apparent as more patients are treated outside the controlled trial setting.
Where Otarmeni fits in a fast-moving gene therapy pipeline for hearing loss
Otarmeni’s approval does not exist in isolation. Several other research groups, including a prominent Fudan University and Harvard collaboration in China, have been conducting their own OTOF gene therapy trials and reported encouraging clinical results before Regeneron’s FDA milestone. Eli Lilly’s Akouos subsidiary has also pursued a competing program. The FDA’s decision to clear Regeneron’s therapy first gives it a significant regulatory head start in the United States, but the broader global pipeline suggests that competition could eventually expand treatment options and potentially drive down costs.
For now, the therapy is best understood as a landmark but early step. It offers an unprecedented alternative to cochlear implants for a narrowly defined group of patients, but it is not a universal treatment for childhood deafness. Only individuals with confirmed biallelic OTOF mutations who meet strict eligibility criteria qualify. The vast majority of children with hearing loss have other genetic or non-genetic causes that Otarmeni does not address.
Families weighing this option will need to balance genuine hope against real uncertainty. The treatment is invasive, lifelong outcome data do not yet exist, and access barriers related to cost and specialized surgical care are likely to be significant in the near term. What the available evidence supports is that Otarmeni represents a major advance whose full impact will become clearer as confirmatory trials report results and the first wave of treated children grows up.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
